Tomorrow's medicines: key programme talks announced for EACPT Stockholm Congess 29 June - 2 July 2019

The next EACPT Congress will be held from 29th June to 2nd July in 2019 in Stockholm as a partnership between the EACPT and the Swedish Society for Pharmacology, Clinical Pharmacology and Therapeutics.

Early bird registration deadline - 10th April 2019.  Register online for the 2019 EACPT Congress in Stockholm

The Congress will address Tomorrow's Healthcare Challenges and will be held at the City Conference Centre - 5 minutes from Stockholm Central Station.

The Congress Reception on the evening of Saturday 29th June, will be held at Stockholm City Hall, the venue of the Nobel Prize banquet.

The Keynote Opening Lecture will be given by the President at the Karolinska Institute, Professor Ole Petter Ottersen, on global health and clinical pharmacology.

Professor Urs Meyer from Switzerland will give the 2019 EACPT Lifetime Achievement Award Lecture based on his work on individual variation in drug response.

Further awards will be presented, including Scientific Awards, including Young Investigator, and EACPT Education Awards.

Around 60 invited speakers are expected from throughout Europe and beyond. Congress keynote lectures will include:

Plenary lectures

Ylva Böttiger:  Clinical pharmacology reaching out - 25 years with EACPT

Ole Petter Ottersen:  Global health research and education in Europe - how can clinical pharmacology contribute?

Harry Sokol:  Gut microbiota - a new actor in pharmacology?

Urs Meyer:  Therapeutic Lessons from Human Individuality

Rosa Giuliani:  Update on treating breast cancer

Jenny Kindblom:  Pediatric clinical trials and their pitfalls 

Tim Nicholson:  New targets in psychopharmacology

Sylvie Laporte:  Meta-epidemiological studies to detect, quantify and adjust for bias in open-label trials

Stefan James:  Innovative ways of performing clinical trials

Björn Wettermark:  How to measure drug utilisation

Cardiovascular prevention

Stephane Laurent:  Update on treating hypertension

Gerard Rongen:  PCSK9 inhibitors - going lower but for whom and at what price? Paul Hjemdahl:  Dual or triple antithrombotic therapy - is two company and three a crowd?

An ageing population

Denis O'Mahoney:  STOPP/START decision support for elderly prescribing

Anne Spinewine:  Prescribing in the frail elderly

 

Workshops

Martin Henriksson:  How to perform a health economic study 

Olof Beck and Markus Meyer: How to measure drug exposure

Jan Marcusson:  How to make on oral presentation and feel good about it

Closing the money gap

Gerd Lärfars:  Horizon scanning frontiers

Andras Inotai:  How to solve money gap to ensure patient access to pharmaceuticals in EU counties

David Webb:  Health economics: big ideas from a small country

Personalized medicine : joint EACPT-EPHAR session

Henk Jan Guchelaar:  Clinical implementation of pharmacogenetics

Viktor Hlavac:  Pharmacogenetics of cancer chemoresistance

Seppo Ylä-Herttuala:  Cardiovascular gene therapy

Martina Schusler-Lenz:  Advanced therapy regulation in the EU

Interprofessional working

Ann Lykkegaard Sørensen:  Interprofessional approach for safer medication in psychiatry

Hanna Seidling:  Benchmarks for successful interdisciplinary collaboration

Debate: Deprescribing is Dangerous

Jamie Coleman:  For; Wade Thompson : Against

Targeting small populations

Caridad Pontes:  barriers to market access, 

Violeta Stoyanova:  drug designation and other regulatory challenges

Critically ill patients

Dario Cattaneo:  Anti-infectives in intensive care

Philippe Vignon:  New sepsis drugs in the pipeline: any reason for hope?

Christoph Stein:  New concepts in opioid analgesia

Antibiotic drug resistance

Johan Mouton:  Antimicrobial resistance. Could PK/PD be the answer?

Alexandra Aubry:  New treatment options for resistent tuberculosis

Polypharmacy: joint session with the Korean Society

Howard Lee:  Polypharmacy in Korea

Ho Sook Kim:  The clinical pharmacology perspectives for the optimal polypharmacy in Korea

Kees Kramers:  Polypharmacy: Acting on the cutting edge of safety, efficacy and compliance

Patient empowerment

Bettina Ryll:  Patient empowerment: Issues with introduction of a new class of drugs

Ann Langius Eklöf:  Smart phones provide smart patients

2020 drug strategy

Jordi Llinares:  achievements and future initiatives; Drug regulation in the 2020s:  Gonzalo Calvo: an academic perspective; Graziella Collu: a pharmaceutical industry perspective

Decision support

Matthew Doogue:  Alert, clinical decision support helping patients and hindering work flow

Lars L Gustafsson:  Clinical pharmacologists with computers - the way forward

Experts at the EACPT Prague Congress discuss Global Health and Access to Safe Medicines

The EACPT 2017 Congress was held in Prague from 24th-27th June with 566 participants from all 5 continents - 28% from beyond the European Region, from Australia to China, Japan and South Korea to the USA. The Congress included 22 sessions with Keynote Lectures on current issues for research, education and clinical practice on safe and effective use of medicines.  

 

Access to Medicines (ensuring the supply chain for access to safe and effective medicines), is a high priority for health professionals, patients and health policy makers and funders within the European and global health perspective. The aim of the session at the EACPT Congress on this theme was to understand challenges and solutions for access to safe and effective medicines.

Panel speakers discuss highlights from the session in the video below.

Pavle Zelic, Jozef Glasa, Mike Isles and Donald Singer

Objectives

1. To understand which organisations and individual categories of health professional are responsible for protecting patients from exposure to unsafe and ineffective medicines.

2. To understand potential weaknesses in the supply chain of medicines from production to dispensing.

3. To be aware of the risks to patients from accessing medicines from unreliable sources, including from unsafe internet 'pharmacies’ and unregulated “healers”.

Speakers and themes

1. Securing the supply chain of medicines: whose responsibility?

Mike Isles, Executive Director,

European Alliance for Access to Safe Medicines

2. Challenges and solutions for policy makers for access to medicines

Professor Jozef Glasa, Institute of Pharmacology, Clinical and Experimental Pharmacology and Institute of Health Care Ethics, Slovak Medical University in Bratislava 

3. Fight against falsified medicines: coordinated actions at EDQM level through the Medicrime Convention

Pavle Zelic, International Cooperation, European Integrations and Public Relations Manager, Medicines and Medical Devices Agency of Serbia

ADAPTSMART: Accelerated Development of Appropriate Patient Therapies -

London, EMA, 17th January 2017: ADAPT SMART is a  platform funded by the European Union's IMI (Innovative Medicines Initiative) for the coordination of Medicines Adaptive Pathways to Patients (MAPPs) activities, involving multi-stakeholder approaches from research through to treatment outcomes.

MAPPs seek to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product life-span in a sustainable fashion.

The European Medicines Agency is today hosting at Canary Wharf in London an expert workshop on ADAPTSMART, with delegates from throughout the European Region, from the Japanese medicines agency and elsewhere.

Topics include:

- appropriate use of medicines

- timely access to innovative medicines and other interventions

- early access medicine schemes

- protected therapeutic schemes e.g. cancer access funds

 - compassionate use

- expanded access pathways

- shortened timelines for approvals

- international comparisons for consequences of inappropriate prescribing - non-compliance with treatment guidelines. Differences will be considered where reimbursement is linked to compliance with prescribing guidelines.

See more on the ADAPTSMART website about key work packages and other aspects.